KTTA Insider Trading Activity and SEC Form 4 Filings
KTTA insider trading summary
Over the past 12 months, insiders at Pasithea Therapeutics Corp. (KTTA) reported 4 open-market purchases worth $203K by 4 insiders and no sales on SEC Form 4. Net insider buying was $203K.
Latest KTTA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Coastlands Capital LP | 10% Owner | Buy | $53K (100,000 @ $0.53) |
| Nov 28, 2025 | Tiago Marques | Chief Executive Officer | Buy | $25K (33,333 @ $0.75) |
| Nov 28, 2025 | Lawrence Steinman | Director | Buy | $100K (133,333 @ $0.75) |
| Nov 28, 2025 | Simon Dumesnil | Director | Buy | $25K (33,333 @ $0.75) |
| May 12, 2025 | Tiago Marques | Chief Executive Officer | Sell | $792 (960 @ $0.82) |
| Jun 2, 2023 | Lawrence Steinman | Director | Buy | $13K (30,000 @ $0.43) |
| Oct 17, 2022 | David Delaney | Insider | Buy | $1K (1,000 @ $1.11) |
| Oct 17, 2022 | Elderhill Corp | Insider | Buy | $1K (1,000 @ $1.11) |
| Oct 17, 2022 | Concord IP2 Ltd. | Insider | Buy | $1K (1,000 @ $1.11) |
| Sep 29, 2022 | Eric Shahinian | Insider | Buy | $8K (6,710 @ $1.16) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.